IJPR  articles are Indexed in SCOPUS (2010 - 2021)Click Here     *Five Years Citation in Google scholar (2016 - 2020) is. 1451*        Now IJPR is Q2 in SJR Ranking     Scopus Coverage of IJPR (2010-2021 Issue 1)            

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
A Systematic Review of Cost Effectiveness of Pembrolizumab Versus Standard Treatment for Metastatic Non-Small Cell Lung Cancer

Author: FITRIANA YULIASTUTI, SUSI ARI KRISTINA, DWI ENDARTI, TRI MURTI HANDAYANI
Abstract: Background: This study aimed to review the available literature on the cost-effectiveness of pembrolizumab versus standard chemotherapy treatment as first-line treatment for metastatic Non-Small Cell Lung Cancer (NSCLC) with Programmed Death Ligand-1 (PD-L1) from multiple paying perspectives. Methods: A systematic review was conducted to identify related studies. Electronic databases used to identify relevant studies are, ScienceDirect, Cochrane and PubMed. This study is limited to English and publications from 2015 to 2020. Study characteristics and result were recorded and compared. Results: An electronic database search yield 35 articles while only 7 studies met the criteria for review. The most widely used method in this research, includes modeling, sensitivity analysis as well as cost-effectiveness analysis were carried out. All studies were evaluated directly cost and used quality-adjusted life years (QALY) and years of life earned, at a discount rate of 3% and 4%. pembrolizumab compared with chemotherapy in a population with PD-L1 TPS =50% ICER US $ US97,621/ QALY; Hongkong $ 110,922/QALY; USA $ US130,155; Switzerland $ 100,000; France $ US96,050.38; China $ 36,493; China $ 136,228.82. The QHES tool was used to confirm the quality of existing studies and showed that the score was 89.14. Conclusion: This literature study suggests that pembrolizumab is a project to be a cost-effective option compared to platinum-based Standard of Care (SoC) chemotherapy as the first-line treatment in adults with metastatic nonsmall cell lung cancer (NSCLC) programmed death ligand-1 (PD-L1).
Keyword: cost effectiveness, pembrolizumab, first-line treatment, metastatic NSCLC
DOI: https://doi.org/10.31838/ijpr/2021.13.02.090
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free